BB BIOTECH AG | Company profile from Hoover's
 
Call Now! 866-464-3202
This is a custom template (Home Pages: Video Center Area - AUTO PLAY WITH MUTED SOUND) that is currently displayed on the following pages: * third column

Video Center

BB BIOTECH AG · Schaffhausen Switzerland · (Swiss: BIO)

Company Description

Vordergasse 3
Schaffhausen
CH-82-00
Switzerland (Map)
Phone: +41-52-624-08-45
Fax: +41-52-624-60-29
Rankings
  • TecDAX
View BB BIOTECH AG Locations On A US MapThis link will open in a new window

BB BIOTECH banks on genetics. The investment firm funds private and public biotechnology companies around the world. BB BIOTECH's portfolio includes significant stakes in about five companies including Actelion and Celgene. The company rounds out its portfolio with smaller stakes in about two-dozen companies, keeping its holdings below 10%. BB BIOTECH prefers to invest in well-managed companies that are within two years of bringing a product to market. The company has some CHF 2.2 billion (approximately $2 billion) under management. Founded in 1993, BB BIOTECH was an early investor in Amgen, one of the biggest biotechnology companies in the world. To read the full description, subscribe now.

Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!

BB BIOTECH AG Reports

No subscription, no problem.
Download presentation-ready reports for this company now.
From company profiles to the competitive landscape, Hoover’s offers immediate access to individual reports.

Key BB BIOTECH AG Financials

Company TypePublic - Swiss: BIO

Headquarters
Fiscal Year-EndDecember
Employees16,400

BB BIOTECH AG Executives

11 executives listed for BB BIOTECH AG's Schaffhausen Switzerland location.
TitleName & BioContact
ChairmanThomas SzucsEmail
Vice ChairmanDavid BaltimoreEmail
Investor RelationsNafida BendaliEmail

Competition

Competitive Landscape for BB BIOTECH AG
Demand is driven primarily by the pace of technological innovation and the number of companies created to commercialize new technologies. The profitability of individual companies depends on successfully choosing and managing a portfolio of investments. Large companies have advantages in attracting investors, developing expertise in multiple technology markets, and funding large deals. Small companies can compete effectively by concentrating on specific market sectors or geographic areas. The average venture capital investment is about $8 million. Individual, or angel, investors, and large companies with strategic interests in early-stage companies are also sources of new venture funding. To read the full description, subscribe now.
Top BB BIOTECH AG Competitors
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!